Nasal Vaccines Against Hepatitis B: An Update

Area of Science:

• Immunology
• Vaccinology
• Hepatology

Background:

• Current injectable hepatitis B vaccines have limitations, including administration method and ineffectiveness against chronic hepatitis B.
• There is a need for improved hepatitis B vaccines that can induce both humoral and cellular immunity, particularly for chronic infections.

Purpose of the Study:

• To review recent advancements in developing intranasal hepatitis B vaccines.
• To discuss potential antigens and adjuvants for intranasal vaccine formulations.
• To evaluate the immune responses elicited by different intranasal vaccine strategies.

Main Methods:

• Review of scientific literature on intranasal hepatitis B vaccine development.
• Analysis of studies focusing on antigens, adjuvants, and formulations.
• Summarization of immune response data, including antibody and cellular responses.

Main Results:

• Intranasal vaccine formulations have shown potential in inducing specific mucosal immune responses (sIgA).
• Studies report balanced Th1/Th2 or Th1-type cellular and humoral immune responses.
• Various promising adjuvants have been identified for enhancing hepatitis B antigen immunogenicity.

Conclusions:

• Intranasal hepatitis B vaccines represent a promising self-administered alternative to current injectable vaccines.
• These vaccines may offer advantages in preventing sexually transmitted hepatitis B and treating chronic infections.
• Further evaluation in animal models is crucial to confirm the efficacy of intranasal vaccines and adjuvants, especially for immunotherapy strategies against chronic hepatitis B.